BR0015172A - Nova combinação compreendendo um agonista adreno receptor de beta 2 (beta 2) e um antagonista receptor de leucotrieno - Google Patents

Nova combinação compreendendo um agonista adreno receptor de beta 2 (beta 2) e um antagonista receptor de leucotrieno

Info

Publication number
BR0015172A
BR0015172A BR0015172-6A BR0015172A BR0015172A BR 0015172 A BR0015172 A BR 0015172A BR 0015172 A BR0015172 A BR 0015172A BR 0015172 A BR0015172 A BR 0015172A
Authority
BR
Brazil
Prior art keywords
beta
receptor antagonist
new combination
agonist
leukotriene receptor
Prior art date
Application number
BR0015172-6A
Other languages
English (en)
Inventor
Jan Trofast
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR0015172A publication Critical patent/BR0015172A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

"NOVA COMBINAçãO COMPREENDENDO UM AGONISTA ADRENO RECEPTOR DE BETA 2 (<225>~ 2~) E UM ANTAGONISTA RECEPTOR DE LEUCOTRIENO". A presente invenção proporciona uma composição farmacêutica, um produto farmacêutico ou um kit farmacêutico compreendendo um primeiro ingrediente ativo que é um agonista adreno receptor de beta 2 (<225>~ 2~) selecionado a partir de formoterol e derivados farmaceuticamente aceitáveis do mesmo, e um segundo ingrediente ativo que é um antagonista receptor de leucotrieno selecionado a partir de zafirlukast, montelukast e seus derivados farmaceuticamente aceitáveis, para utilização no tratamento de disfunções inflamatórias.
BR0015172-6A 1999-11-03 2000-10-27 Nova combinação compreendendo um agonista adreno receptor de beta 2 (beta 2) e um antagonista receptor de leucotrieno BR0015172A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9903995A SE9903995D0 (sv) 1999-11-03 1999-11-03 New combination
PCT/SE2000/002115 WO2001032163A1 (en) 1999-11-03 2000-10-27 NEW COMBINATION COMPRISING A BETA 2 (β)2 ADRENO RECEPTOR AGONIST AND A LENKOTRIENE RECEPTOR ANTAGONIST

Publications (1)

Publication Number Publication Date
BR0015172A true BR0015172A (pt) 2002-06-18

Family

ID=20417605

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0015172-6A BR0015172A (pt) 1999-11-03 2000-10-27 Nova combinação compreendendo um agonista adreno receptor de beta 2 (beta 2) e um antagonista receptor de leucotrieno

Country Status (13)

Country Link
EP (1) EP1242065A1 (pt)
JP (1) JP2003513037A (pt)
KR (1) KR20020050254A (pt)
CN (1) CN1387431A (pt)
AU (2) AU1652601A (pt)
BR (1) BR0015172A (pt)
CA (1) CA2388657A1 (pt)
IL (1) IL149365A0 (pt)
MX (1) MXPA02004334A (pt)
NO (1) NO20022103L (pt)
SE (1) SE9903995D0 (pt)
WO (2) WO2001032166A1 (pt)
ZA (1) ZA200203178B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
PE20050130A1 (es) * 2002-08-09 2005-03-29 Novartis Ag Compuestos organicos
GB0312148D0 (en) 2003-05-28 2003-07-02 Aventis Pharma Ltd Stabilized pharmaceutical products
GB0315889D0 (en) 2003-07-08 2003-08-13 Aventis Pharma Ltd Stable pharmaceutical products
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
JP2007531743A (ja) * 2004-04-05 2007-11-08 セプラコア インコーポレーテッド 他の薬剤と組合せた（ｒ，ｒ）−ホルモテロール
ES2245612B1 (es) * 2004-06-29 2007-08-16 Universidad De Barcelona Nuevo uso terapeutico del formoterol.
ES2570332T3 (es) * 2005-03-16 2016-05-17 Meda Pharma Gmbh & Co Kg La combinación de anticolinérgicos y antagonistas del receptor de leucotrieno para el tratamiento de enfermedades respiratorias
CA2838435A1 (en) 2011-06-06 2012-12-13 Chiesi Farmaceutici S.P.A. Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
KR102192739B1 (ko) * 2012-12-05 2020-12-18 키에시 파르마슈티시 엣스. 피. 에이. 포스포디에스테라제 억제제로서 1-페닐-2-피리디닐 알킬 알코올의 유도체
JP5846185B2 (ja) 2013-11-21 2016-01-20 大日本印刷株式会社 貫通電極基板及び貫通電極基板を用いた半導体装置
PT109030B (pt) * 2015-12-15 2019-09-25 Hovione Farmaciência, S.A. Preparação de partículas inaláveis de zafirlucaste

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9604752D0 (sv) * 1996-12-20 1996-12-20 Astra Ab Formulation and use
EA001797B1 (ru) * 1997-03-13 2001-08-27 Мерк Энд Ко., Инк. Хинолиновые антагонисты лейкотриенов
SE9704644D0 (sv) * 1997-12-12 1997-12-12 Astra Ab New use

Also Published As

Publication number Publication date
CN1387431A (zh) 2002-12-25
SE9903995D0 (sv) 1999-11-03
ZA200203178B (en) 2003-07-22
NO20022103D0 (no) 2002-05-02
WO2001032166A1 (en) 2001-05-10
NO20022103L (no) 2002-05-02
EP1242065A1 (en) 2002-09-25
KR20020050254A (ko) 2002-06-26
AU1321401A (en) 2001-05-14
MXPA02004334A (es) 2002-11-07
WO2001032163A1 (en) 2001-05-10
JP2003513037A (ja) 2003-04-08
CA2388657A1 (en) 2001-05-10
IL149365A0 (en) 2002-11-10
AU1652601A (en) 2001-05-14

Similar Documents

Publication Publication Date Title
Coukell et al. Amisulpride: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of schizophrenia
BR0015172A (pt) Nova combinação compreendendo um agonista adreno receptor de beta 2 (beta 2) e um antagonista receptor de leucotrieno
BR9806801A (pt) Utilização de um antagonista de receptores cb1, composição farmacêutica, e, estojo para o tratamento de distúrbios da apetência
AU4818000A (en) Substituted 4-oxo-quinoline-3-carboxamides: gaba brain receptor ligands
AU2001285451A1 (en) 2,4-substituted pyridine derivatives
BRPI0314308B8 (pt) antagonistas de opióide, seus usos, e composição farmacêutica
BR9711805A (pt) Compostos e métodos para providenciar preparações farmacologicamente ativas e uso dos mesmos
BRPI0113669B8 (pt) n-hidróxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]-amino]metil]fenil]-2e-2-propenamida, composição farmacêutica compreendendo o mesmo e uso
BR0015346A (pt) Formulação farmacêutica contendo tolterodina e seu uso
BR0016275A (pt) Combinações farmacêuticas e seu uso no tratamento de distúrbios gastrointestinais
BR0210929A (pt) Derivados de indol com afinidade para o receptor 5-ht6
BR9812886A (pt) Uso de um atagonista de recptor de 5-ht3 ou de um seu derivado farmaceuticamente aceitável, processo para tratamento de ibs em fêmeas não-constipadas, e, antagonista de recpetor de 5-ht3 ou seu derivado farmaceuticamente aceitável
NO20100041L (no) Anvendelse av AT-1 reseptorantagonist eller AT-2 reseptormodulator for behandling av sykdommer assosiert med en okning av AT-1 eller AT-2 reseptorer
BR0016385A (pt) Compostos ou suas combinações que tem atividade inibidora da recaptação da seratonina e de um antagonista, agonista inverso ou agonista parcial de 5-ht2c; utilização dos mesmos; composição farmacêutica e método
BR0017338A (pt) Composto, processo para preparar um composto, composição farmacêutica, e métodos para tratar um paciente, para inibir quimiotaxia celular promovida com c5a, para localizar receptores de c5a em um tecido, e para reduzir a gravidade ou frequência de uma ou mais sequelas inflamatórias de transplante de órgão
BRPI0414558A (pt) composição farmacêutica compreendendo um antagonista do receptor p2x7 e uma droga antiinflamatória não esteróide
BR9908510A (pt) Uso de um composto, composto, processo para a preparação de um composto, composição farmacêutica, e, processo de tratar um paciente que sofre de, ou em risco de, uma doença micobacteriana
BR9915111A (pt) Partìculas revestidas de ibuprofeno cristalinogranulado
ATE417838T1 (de) Arylsulfonyl-derivate mit 5-ht 6-rezeptor- affinität
BR0015540A (pt) Antagonistas do receptor de adenosina e métodos de preparação e uso dos mesmos
BRPI0413013A (pt) composto, seus sais, solvatos, e derivados farmaceuticamente funcionais, composição farmacêutica, uso de um composto, e, métodos para o tratamento ou profilaxia de condições ou distúrbios, e de doenças
BR0317771A (pt) Composição farmacêutica, uso da mesma, e, método de tratar distúrbios em um paciente
AR024232A1 (es) Bromhidrato de eletriptan monohidratado, composicion farmaceutica, su uso en la preparacion de medicamentos y procedimiento para su preparacion
BR9810337A (pt) Utilização de um antagonista especìfico dos receptores 5ht2 para a preparação de medicamentos úteis no tratamento da sìndrome de apnéia do sono
EA200100089A1 (ru) Предотвращение рецидива мигрени

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]